Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
Table 5
Subgroup meta-analysis of TEAEs of special interest based on different treatment regimens.
Hypertension (95%CI)
Proteinuria (95%CI)
CHF (95%CI)
Renal failure (95%CI)
GI haemorrhage (95%CI)
Bleeding or haemorrhage (95%CI)
VTE (95%CI)
Liver injury or failure (95%CI)
Fistula (95%CI)
ATE (95%CI)
IRR (95%CI)
Epistaxis (95%CI)
GI perforation (95%CI)
Healing complication (95%CI)
Pulmonary haemorrhage (95%CI)
DOC+R vs. DOC+P
Grade 1–2
2.66 [2.02, 3.51]
4.12 [2.08, 8.14]
1.42 [0.57, 3.57]
0.92 [0.45, 1.90]
1.76 [0.82, 3.78]
2.71 [2.23, 3.30]
0.47 [0.30, 0.74]
—
—
0.77 [0.40, 1.51]
0.95 [0.70, 1.28]
3.28 [2.25, 4.79]
2.98 [0.60, 14.80]
—
1.05 [0.69, 1.60]
Grade ≧3
3.22 [1.95, 5.32]
3.31 [0.37, 29.22]
2.71 [0.58, 12.76]
1.80 [0.38, 8.45]
1.28 [0.32, 5.21]
0.84 [0.46, 1.53]
0.51 [0.29, 0.90]
—
—
1.10 [0.46, 2.61]
1.14 [0.55, 2.38]
1.97 [0.18, 21.83]
2.48 [0.48, 12.81]
—
0.99 [0.37, 2.64]
PTX+R vs. PTX+P
Grade 1–2
2.16 [1.37, 3.40]
2.19 [1.54, 3.12]
2.42 [0.65, 9.00]
1.49 [0.68, 3.26]
1.40 [0.83, 2.34]
2.93 [2.16, 3.96]
0.72 [0.31, 1.71]
1.57 [1.13, 2.16]
2.50 [0.12, 52.32]
1.30 [0.31, 5.52]
1.80 [0.84, 3.90]
—
0.69 [0.09, 5.40]
—
—
Grade ≧3
3.30 [1.96, 5.57]
4.69 [0.86, 25.68]
1.38 [0.28, 6.81]
2.03 [0.50, 8.19]
1.70 [0.77, 3.75]
1.38 [0.69, 2.75]
0.70 [0.29, 1.68]
1.02 [0.60, 1.76]
1.49 [0.06, 36.86]
0.85 [0.21, 3.41]
3.56 [0.41, 30.54]
—
9.17 [0.49, 170.95]
—
—
BSC+R vs. BSC+P
Grade 1–2
2.08 [1.31, 3.30]
3.45 [2.08, 5.74]
0.33 [0.01, 8.16]
0.93 [0.44, 1.96]
1.65 [0.77, 3.52]
2.30 [1.62, 3.25]
0.92 [0.41, 2.07]
2.32 [1.61, 3.33]
0.81 [0.11, 6.17]
1.52 [0.44, 5.23]
2.35 [0.43, 12.77]
4.66 [1.37, 15.82]
0.97 [0.09, 10.86]
0.33 [0.01, 8.16]
3.01 [0.84,10.80]
Grade ≧3
3.30 [1.94, 5.61]
5.72 [1.08, 30.38]
0.40 [0.05, 3.23]
2.01 [0.50, 8.14]
0.79 [0.41, 1.52]
0.99 [0.58, 1.67]
#0.33 [0.12, 0.94]
0.94 [0.67, 1.32]
0.49 [0.03, 7.83]
1.35 [0.33, 5.53]
7.05 [0.36, 137.15]
1.46 [0.06, 36.13]
0.64 [0.14, 2.90]
—
0.74 [0.12, 4.57]
TEAEs = treatment-emergent adverse events, CI = confidence interval, DOC = docetaxel, PTX = paclitaxel, BSC = best supportive care, RAM = ramucirumab, P = placebo, CHF = congestive heart failure, IRR = = infusion-related reaction, VTE = venous thromboembolic, ATE = arterial thromboembolic, and GI = gastrointestinal.# Higher risk in control group. ,, and .
